Monitoring measurable residual disease in NUP98 :: NSD1 ‐positive acute myeloid leukemia
Pediatrics International · 2025-01 · 67 (1)
DOI: 10.1111/ped.15859 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatrics International, online erschienen am 04.02.2025. Verfasst von Ikuo Okuchi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Bunkyo-Ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Neoplasm, Residual, Leukemia, Myeloid, Acute, Nuclear Pore Complex Proteins, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: Japan leukemia research fund.
Abstract (Originalsprache)
Background
NUP98 fusion genes are detected in acute myeloid leukemia (AML) subgroups that have a poor prognosis. An appropriate therapeutic approach should therefore be established. Treatment intensification according to the minimal residual disease (MRD) level can lead to a better prognosis in patients with acute lymphoblastic leukemia (ALL). However, the importance of MRD monitoring in the patient with NUP98‐positive AML is unclear.
Methods
This study aimed to develop a digital droplet polymerase chain reaction (ddPCR) method for monitoring NUP98 :: NSD1 ‐positive leukemic cells and to report its utility compared with the results of NUP98 split fluorescence in situ hybridization (FISH).
Results
The results of NUP98 :: NSD1 ddPCR correlated with those of NUP98 split FISH and were more sensitive than NUP98 split FISH. The sensitivity of ddPCR was 0.001%, equivalent to 1 in 1 × 10 5 cells. The MRD level of NUP98 :: NSD1, measured by ddPCR, correlated well with relapse.
Conclusion
The use of ddPCR to target NUP98 :: NSD1 chimera mRNA for MRD monitoring would be beneficial for NUP98 :: NSD1 AML treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Bunkyo-Ku, Tokyo, Japan.
- Department of Child Health and Development, Tokyo Medical and Dental University (TMDU), Bunkyo-Ku, Tokyo, Japan.
- Department of Transfusion Medicine and Cell Therapy, Tokyo Medical and Dental University Hospital, Bunkyo-Ku, Tokyo, Japan.
ORCID-Profile: Takahiro Kamiya, Akihiro Hoshino, Takeshi Isoda, Hirokazu Kanegane, Masatoshi Takagi
Förderung
- Japan leukemia research fund
Zitieren
APA
Okuchi, I., Nishimura, A., Kamiya, T., Sasaki, M., Yamashita, M., Hoshino, A., Kajiwara, M., Isoda, T., Kanegane, H., Morio, T., & Takagi, M. (2025). Monitoring measurable residual disease in NUP98 :: NSD1 ‐positive acute myeloid leukemia. Pediatrics International, 67(1). https://doi.org/10.1111/ped.15859
Vancouver
Okuchi I, Nishimura A, Kamiya T, Sasaki M, Yamashita M, Hoshino A, et al. Monitoring measurable residual disease in NUP98 :: NSD1 ‐positive acute myeloid leukemia. Pediatrics International. 2025;67(1). doi:10.1111/ped.15859
BibTeX
@article{Okuchi2025,
author = {Okuchi, Ikuo and Nishimura, Akira and Kamiya, Takahiro and Sasaki, Makiko and Yamashita, Motoi and Hoshino, Akihiro and Kajiwara, Michiko and Isoda, Takeshi and Kanegane, Hirokazu and Morio, Tomohiro and Takagi, Masatoshi},
title = {Monitoring measurable residual disease in NUP98 :: NSD1 ‐positive acute myeloid leukemia},
journal = {Pediatrics International},
year = {2025},
volume = {67},
number = {1},
doi = {10.1111/ped.15859}
}
EUVIMED